AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zura Bio, a clinical-stage biotechnology company, has a market cap of $239.92 million and is pre-revenue. It has strong short-term financial health, with assets surpassing liabilities, and is debt-free. Despite high share price volatility and unprofitable status, the company has a sufficient cash runway for over three years. Recent executive changes include Kim Davis stepping in as interim CEO due to Robert Lisicki's medical leave.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet